Lin BioScience Receives FDA Fast Track Designation for LBS-007
Lin BioScience, a clinical-stage biopharmaceutical company focused on developing innovative therapies for acute leukemia, announced that its lead pipeline candidate, LBS-007, has been granted Fast Track Designation by the FDA for the treatment of acute myeloid leukemia. The company is currently conducting a Phase I/II trial of LBS-007 in patients with relapsed or resistant acute leukemias across the U.S., Australia, and Taiwan. In addition to Fast Track Designation, Lin BioScience has also received Orphan Drug Designation (ODD) from the FDA for both AML and acute lymphocytic leukemia.
Dr. Tom Lin, C...